clinical trial · NCT03069378
A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma
SarcomaEpithelioid SarcomaCutaneous AngiosarcomaTalimogene Laherparepvec (T-VEC)Pembrolizumab
brief summary
The purpose of this study is to determine how well the combination of therapy of talimogene laherparepvec (T-VEC) and pembrolizumab works in the treatment of patients with sarcoma.
started
Mar 3, 2017
primary completion
Jul 22, 2025
completion
Mar 1, 2026
last updated
Oct 29, 2025
official title
A Phase II Study of Talimogene Laherparepvec (T-VEC) Administered Concurrently With the Anti-PD1 Monoclonal Antibody Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol